Key result
Cluster analysis of Japanese athletes with asthma identified three distinct phenotypes (Cluster 1: 32%, Cluster 2: 44%, Cluster 3: 24%) with varying atopic features, pulmonary function, and treatment responses.
Why the study?
Does treatment with ICS or ICS+LABA improve pulmonary function and biomarkers in different phenotypic clusters of Japanese athletes with asthma?
Observational (n=104)
Does treatment with ICS or ICS+LABA improve pulmonary function and biomarkers in different phenotypic clusters of Japanese athletes with asthma?
Japanese athletes with asthma can be classified into three distinct phenotypic clusters that show differential responses to inhaled corticosteroid therapy.
Answers are grounded in this paper and cite their sources.
Suggests phenotype-guided inhaled corticosteroid therapy may optimize asthma management in athletes; leaves open whether.
Asthma in athlete populations such as Olympic athletes has various pathogeneses. However, few reports are available on the features of asthma in the athlete population in clinical practice. In this study, we focused on classifying asthma in Japanese athlete population. We performed a cluster analysis of data from pulmonary function tests and clinical biomarkers before administering inhaled corticosteroids (ICS) therapy in athlete population of individuals diagnosed with asthma (n = 104; male, 76.9%; median age, 16.0 years), based on respiratory symptoms and positive data on methacholine provocation tests. We also compared backgrounds, sports types, and treatments between clusters. Three clusters were identified. Cluster 1 (32%) comprised athletes with a less atopic phenotype and normal pulmonary function. Cluster 2 (44%) comprised athletes with a less atopic phenotype and lower percent predicted forced expiratory volume in 1 s (%FEV1) values, despite less symptomatic state. Cluster 3 (24%) comprised athletes with a strong atopic phenotype such as high eosinophil count in the blood and total serum immunoglobulin E level. After treatment with ICS or ICS plus long-acting β-adrenergic receptor agonist for 6–12 months, %FEV1 values were significantly improved in Cluster 2 athletes, whereas Cluster 3 athletes had a significant decrease in the fraction of exhaled nitric oxide compared to pretreatment values. These data suggest three clusters exist in Japanese athlete population with asthma. Between the clusters, the characteristics differed with regard to symptoms, atopic features, and lower %FEV1 values. The pathogeneses between clusters may vary depending on the inflammation type and airway hyperresponsiveness.
No takes yet. Share an insight, caveat, or question.
Tsukioka et al. (2017) conducted an observational in Asthma (n=104). Asthma phenotypes vs. Between clusters was evaluated on Identification of asthma clusters and response to ICS therapy. Cluster analysis of Japanese athletes with asthma identified three distinct phenotypes (Cluster 1: 32%, Cluster 2: 44%, Cluster 3: 24%) with varying atopic features, pulmonary function, and treatment responses.
Synapse has enriched 10 related papers. Consider them for comparative context: